Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 5 | Arthritis Research & Therapy

Figure 5

From: Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome

Figure 5

LTBR-antagonism from 8 to16 weeks reduced the number of HEV in lacrimal glands and the uptake of CFSE-labeled lymphocytes into lacrimal glands. Immuno-peroxidase visualized HEV (brown) after immunostaining with MECA-79 monoclonal antibody against PNAd in paraffin sections of lacrimal glands (NT = no treatment) (a-c). The bar in (a-c) indicates 100 μm. Fluorescence photomicrograph of a lacrimal gland with B-cells (anti-B220, red) and CFSE-labeled cells indicated by arrowheads (CFSE, green) (d). Quantification by FACS-analysis of CFSE-labeled lymphocytes among all lymphocytes isolated from lacrimal glands or cervical lymph nodes collected from mice (n = 4) that had been treated for 8 weeks with MOPC-21 (open bars) or LTBR-Ig (black bars). Qualitative assessment of ablation of MECA-79 stained HEV by LTBR-Ig treatments was performed more than five times. Quantitation of CFSE cell uptake was performed twice. CFSE, carboxyfluorescein succinimidyl ester; FACS, flow cytometry; HEV, high endothelial venule; LTBR, lymphotoxin-beta receptor; LTBR-Ig; lymphotoxin-beta receptor-mouse immunoglobulin (Fc) chimeric inhibitor.

Back to article page